GlySens Incorporated is a medical device and biotechnology company developing a glucose monitoring system designed to enables people with diabetes to gain better control over the disease using the firm's long term continuous glucose monitoring system. The GlySens fully implanted sensorâdemonstrated up to 18 month lifetime in preclinical testingâwirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance. For those living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGMTM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. Developed n partnership with University of California, San Diego, GlySens ICGM system is currently undergoing clinical evaluation; initial human implant trials have been completed, and preparations for additional human trials are underw
